EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study

Meghan K Gerety iD, Vivek Charu iD, Madison Simmons iD, Nicholas J Seewald iD, Dorey A Glenn iD, Douglas E Schaubel iD, Abigail R Smith iD, Dhruti Chen iD, Louis-Philippe Laurin iD, Michelle Denburg, Lawrence B Holzman, Laurence H Beck iD und 2 weitere

Kidney360 · 2026-10 · 7 (10) · 2324-2334

DOI: 10.34067/kid.0000001265 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Kidney360, online erschienen am 10.07.2026. Verfasst von Meghan K Gerety und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philad…. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Rituximab, Calcineurin Inhibitors, Immunosuppressive Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Comparative treatment effects for rituximab and calcineurin inhibitors on real-world long-term outcomes were estimated. Rituximab was associated with better preservation of long-term kidney function in Cure Glomerulonephropathy patients with membranous nephropathy. Treatments captured real-world prescribing practices, and observations pertain to a broad, pragmatic population relevant to clinical practice.

Background

Clinical trials in rare glomerular disease may establish short-term treatment efficacy but are limited by small sample sizes and short study duration. Observational data are needed to assess longer-term outcomes and can provide insights into real-world prescribing practices. This study applied modern statistical methods to real-world data from the Cure Glomerulonephropathy network to compare the effectiveness of rituximab and calcineurin inhibitors on long-term primary membranous nephropathy outcomes.

Methods

CureGN participants with biopsy-confirmed primary membranous nephropathy who initiated either of the two treatments at least 6 months after any previous immunosuppressant exposure were eligible. Inverse probability-of-treatment weighting balanced covariates at treatment initiation. Inverse probability-of-censoring weights accounted for censoring individuals if another immunosuppressant was started during follow-up. Outcomes included time from treatment initiation to composite kidney disease progression (40% decline in eGFR, KRT, or eGFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousRituximabCalcineurin InhibitorsImmunosuppressive AgentsHumansFemaleMaleMiddle AgedTreatment OutcomeDisease ProgressionAdultGlomerular Filtration RateProteinuriaRecurrence

Stichwörter der Autor:innen

biostatisticscohort studiesepidemiological methodsepidemiology and outcomesglomerular diseasesimmunosuppressionmembranous nephropathyoutcomesproteinuria

Substanzen

RituximabCalcineurin InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California.
  • Howard University, Washington, DC.
  • Division of Nephrology and Hypertension, UNC Kidney Center, Chapel Hill, North California.
  • Division of Biostatistics and Informatics, Department of Preventive Medicine, Northwestern University, Chicago, Illinois.

ORCID-Profile: Meghan K Gerety, Vivek Charu, Madison Simmons, Nicholas J Seewald, Dorey A Glenn, Douglas E Schaubel, Abigail R Smith, Dhruti Chen, Louis-Philippe Laurin, Laurence H Beck, Jarcy Zee

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Gerety, M. K., Charu, V., Simmons, M., Seewald, N. J., Glenn, D. A., Schaubel, D. E., Smith, A. R., Chen, D., Laurin, L. P., Denburg, M., Holzman, L. B., Beck, L. H., Mariani, L. H., & Zee, J. (2026). Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study. Kidney360, 7(10), 2324-2334. https://doi.org/10.34067/kid.0000001265

Vancouver

Gerety MK, Charu V, Simmons M, Seewald NJ, Glenn DA, Schaubel DE, et al. Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study. Kidney360. 2026;7(10):2324-2334. doi:10.34067/kid.0000001265

BibTeX
@article{Gerety2026,
  author = {Gerety, Meghan K and Charu, Vivek and Simmons, Madison and Seewald, Nicholas J and Glenn, Dorey A and Schaubel, Douglas E and Smith, Abigail R and Chen, Dhruti and Laurin, Louis-Philippe and Denburg, Michelle and Holzman, Lawrence B and Beck, Laurence H and Mariani, Laura H and Zee, Jarcy},
  title = {Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study},
  journal = {Kidney360},
  year = {2026},
  volume = {7},
  number = {10},
  pages = {2324--2334},
  doi = {10.34067/kid.0000001265}
}
Kostenlos starten →